Head-To-Head Survey: QHSLab (OTCMKTS:USAQ) vs. ChronoScale Corporation Common Stock (NASDAQ:CHRN)

QHSLab (OTCMKTS:USAQ) and ChronoScale Corporation Common Stock (NASDAQ:CHRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Volatility and Risk

QHSLab has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, ChronoScale Corporation Common Stock has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Insider & Institutional Ownership

6.4% of ChronoScale Corporation Common Stock shares are held by institutional investors. 74.2% of QHSLab shares are held by company insiders. Comparatively, 6.9% of ChronoScale Corporation Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares QHSLab and ChronoScale Corporation Common Stock”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QHSLab	$2.69 million	1.89	$460,000.00	$0.03	15.02
ChronoScale Corporation Common Stock	$12.80 million	5.29	-$11.69 million	($5.38)	-3.54

QHSLab has higher earnings, but lower revenue than ChronoScale Corporation Common Stock. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for QHSLab and ChronoScale Corporation Common Stock, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QHSLab	0	0	0	0	0.00
ChronoScale Corporation Common Stock	1	1	0	0	1.50

ChronoScale Corporation Common Stock has a consensus price target of $6.00, suggesting a potential downside of 68.47%. Given ChronoScale Corporation Common Stock’s stronger consensus rating and higher probable upside, analysts plainly believe ChronoScale Corporation Common Stock is more favorable than QHSLab.

Profitability

This table compares QHSLab and ChronoScale Corporation Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QHSLab	15.60%	-27.74%	-6.98%
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%

Summary

QHSLab beats ChronoScale Corporation Common Stock on 7 of the 13 factors compared between the two stocks.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.